Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20023512HPVENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS20039145HPVENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS20049105HPVENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS20044977HPVENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS20023526HPVENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS20038652HPVENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS44009700HTLV-1ENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS44023101HTLV-1ENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS44049322HTLV-1ENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TVIS44046507HTLV-1ENSG00000165995.24protein_codingCACNB2NoNo783Q08289
TCGA Plot Options
Drug Information
GeneCACNB2
DrugBank IDDB06712
Drug NameNilvadipine
Target IDBE0002354
UniProt IDQ08289
Regulation Typeinhibitor
PubMed IDs7898101; 1283184; 20933604
CitationsRosenthal J: Nilvadipine: profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S92-107.@@Honerjager P, Seibel K: Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist. J Cardiovasc Pharmacol. 1992;20 Suppl 6:S15-21.@@Araie M, Mayama C: Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8.
GroupsApproved; Investigational
Direct ClassificationDihydropyridinecarboxylic acids and derivatives
SMILESCOC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
Pathways
PharmGKBPA165958385
ChEMBLCHEMBL517427